Coinbase stock slides as bitcoin slips under $90,000; Bermuda “onchain economy” plan in focus
20 January 2026
1 min read

Coinbase stock slides as bitcoin slips under $90,000; Bermuda “onchain economy” plan in focus

New York, January 20, 2026, 13:14 EST — Regular session

Shares of Coinbase Global dropped 5.2% to $228.68 in early afternoon trading Tuesday, following a wider slump in crypto prices. Bitcoin slipped 3.6%, while ether tumbled 6.7%.

This move is significant since Coinbase stands out as one of the clearest U.S.-listed plays on crypto trading volume. Token price shifts and volatility typically drive trading activity, which in turn impacts the exchange’s revenue.

Tuesday saw a pullback from risk assets as investors reacted to U.S. President Donald Trump’s fresh bid to buy Greenland and looming tariff threats against European countries. These moves unsettled markets, driving capital toward safer bets. 1

Separately, Coinbase acknowledged that some users are experiencing delays when sending and receiving funds on the Ronin Network. 2

Ronin, designed for gaming, is an Ethereum Virtual Machine-compatible blockchain launched by Sky Mavis, the team behind Axie Infinity, according to the project’s documentation. 3

Coinbase grabbed headlines this week with a major international partnership: Bermuda’s government announced plans to become the world’s first “fully onchain” national economy, relying on Circle and Coinbase for infrastructure and tools. The term “onchain” refers to using blockchain as the backbone for everyday financial transactions. Circle is promoting USDC, its dollar-pegged stablecoin, to speed up and cut costs on payments. Bermuda Premier David Burt described the move as a way to “create opportunity” and “lower costs,” while Coinbase CEO Brian Armstrong said the company is “excited to support” the shift. 4

Despite the longer-term rally, crypto-linked stocks slipped today. Strategy fell 8.2%, while Robinhood Markets dropped 1.5%, following Coinbase’s decline.

The recent selloff has reignited a familiar debate among investors: Is bitcoin “digital gold” or just a leveraged gamble? Duke University finance professor Campbell Harvey told Investopedia in a paper that bitcoin “is hardly a safe-haven asset.” Bitunix analyst Dean Chen added that the wider market continues to treat bitcoin as a “high-beta risk asset.” 5

But the connection runs both ways. Should crypto prices steady and volatility pick up enough to boost trading, Coinbase could see a swift rebound. And if the macroeconomic shock eases, that risk appetite which had vanished might surge back in just as quickly.

Traders are focused on the political calendar and the charts for now. February 1 is front and center after Trump’s tariff warning, with investors scanning for any hint of easing or a broader trade conflict. 6

Coinbase is set to release its quarterly results on February 12, with the earnings call covering both Q4 and the full year scheduled for after the market close. 7

Stock Market Today

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

7 February 2026
Applied Digital Corporation shares jumped 25.52% Friday to $34.95, then slipped to $34.60 after hours. The company reported fiscal Q2 revenue up 250% to $126.6 million and signed leases for 600 MW of data center capacity in North Dakota. Applied Digital broke ground on a new 430‑MW campus in the southern U.S. in January. Financing includes a $100 million promissory note with 8% interest, paid in kind.
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
AbbVie stock slips as traders watch Epkinly data and the next earnings clock
Previous Story

AbbVie stock slips as traders watch Epkinly data and the next earnings clock

Thermo Fisher stock slips as Australia opens Clario deal review — what investors watch next
Next Story

Thermo Fisher stock slips as Australia opens Clario deal review — what investors watch next

Go toTop